Table 1.
Characteristics of children started on antiretroviral treatment ( n = 26)
| Characteristics | Numbers(interval) | Percentage |
|---|---|---|
| Age at start ART (years, median)a |
7.7 (1.5–12) |
|
| <2 years |
2 |
7.7% |
| 2–4.9 years |
4 |
15.3% |
| 5–14 years |
20 |
77% |
| Sex (male/female) |
16/10 |
61.5%/38.5% |
| Reason for ART |
|
|
| WHO stage III-IV |
6 |
36.5% |
| Baseline CD4 count <15% |
20 |
63.5% |
| Naïve ART regimen |
|
|
| D4T/3TC/NVP (EFV) |
8 |
30.8% |
| AZT/3TC/NVP |
18 |
69.2% |
| Time on ART (months, median)a,b |
41 (18–72.3) |
|
| <2 yearsb |
5 |
19.2% |
| 2 years to <3 yearsb |
7 |
26.9% |
| 3 years to <4 yearsb |
6 |
23.1% |
| >4 yearsb |
8 |
30.8% |
| HIV transmission |
|
|
| Blood product or transfusion recipient |
9 |
34.6% |
| Mother-to-child transmission | 17 | 65.4% |
aValues are expressed as median (interquartile range).
bAs of 30 December 2008 (closing date of dataset).
WHO, World Health Organization; ART, antiretroviral therapy; D4T, stavudine; 3TC, lamivudine; AZT, zidovudine;NVP, nevirapine; EFV, efavirenz.